Gino In

Title(s)Associate Professor of Clinical Medicine
SchoolKeck School of Medicine of Usc
AddressNOR 3440 NTT
Health Sciences Campus
Los Angeles CA 90089-9324
Phone+1 323 226 7622
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    University of Southern California, Los Angeles, CAFellowship2016Hematology/Oncology
    SUNY Downstate Medical Center, Brooklyn, NYResidency2011Internal Medicine
    SUNY Downstate Medical Center, Brooklyn, NYInternship2010
    Ross University, North Brunswick Township, NJMD2010Medicine
    Emory University, Atlanta, GAMPH2006Environmental/Occupational Health
    Emory University, Atlanta, GABS2002
    Collapse awards and honors
    University of Southern CaliforniaChief Medical Oncology Fellow

    Collapse Overview 
    Collapse overview
    Gino K. In, MD, MPH, is a medical oncologist who specializes in solid tumor and cutaneous oncology. He completed his fellowship training in hematology and oncology at the University of Southern California, Keck School of Medicine, where he was the chief medical oncology fellow. He subsequently joined the USC Norris Comprehensive Cancer Center, and now serves as Assistant Professor of Clinical Medicine in the Division of Oncology, and Assistant Professor of Dermatology. Dr. In’s research focus includes the multi-disciplinary management of melanoma and other skin cancers, including cutaneous squamous cell carcinoma, basal cell carcinoma and Merkel cell carcinoma. He has a specific interest in non-UV related melanoma subtypes and intratumoral therapies. Dr. In is the lead primary investigator for cutaneous oncology clinical trials at USC, including studies through the National Cancer Institute, California Cancer Consortium, and Southwest Oncology Group.

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Comprehensive Profiling of Acral Lentiginous Melanoma Reveals Downregulated Immune Activation Compared to Cutaneous Melanoma. Pigment Cell Melanoma Res. 2025 May; 38(3):e70027. Wang SJ, Xiu J, Butcher KM, DeClerck BK, Kim GH, Moser J, Gibney GT, Hernandez-Aya LF, Lutzky J, Abdulla F, Margolin KA, Possik PA, Robles-Espinoza CD, Ito F, In GK. PMID: 40405404; PMCID: PMC12099029.
      View in: PubMed   Mentions:    Fields:    
    2. Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301). J Clin Oncol. 2025 May 20; 43(15):1800-1809. Diab A, Ascierto PA, Maio M, Abdel-Wahab R, Negrier S, Mortier L, Arenberger P, Dalle S, Krajsova I, de la Cruz L, Leccia MT, Guida M, Lebbe C, Grob JJ, Butler MO, In GK, Loquai C, Walker JWT, Atkinson V, Kapiteijn E, Haferkamp S, Chunduru S, Rahimian S, Guidoboni M, Robert C. PMID: 40048691.
      View in: PubMed   Mentions:    Fields:    Translation:CTClinical Trials
    3. Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma. Br J Dermatol. 2025 Jan 24; 192(2):316-326. McGillivray E, Ashouri K, Chatziioannou E, Gallegos JAO, Zarka J, Kechter J, Hwang AS, Zhang K, Barros M, Yeh J, Okazaki I, Crocker AB, Maeda T, Park SJ, Choi J, Andreoli M, Darwish T, Savage DJ, Kim KB, Gupta J, Shen J, Shirai K, Choi A, Pai L, Vazquez VL, Moser J, Amaral T, Hernandez Aya LF, Lutzky J, Najjar YG, Costello CM, Mangold AR, Bhatia S, Gibney GT, Farma JM, Daniels GA, Sosman J, Chandra S, Mangla A, Bollin K, Possik PA, Robles-Espinoza CD, Ito F, In GK. PMID: 39438074; PMCID: PMC11758508.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    4. Acral Lentiginous Melanoma. Part I. Epidemiology, Etiology, Clinical Presentation, and Diagnosis. J Am Acad Dermatol. 2025 Jan 08. Thakker S, Jaguan D, Belzberg M, Gulati N, Campbell JR, DeClerck BK, In GK, Patel VA. PMID: 39793708.
      View in: PubMed   Mentions:    Fields:    
    5. Acral Lentiginous Melanoma. Part II. Staging, Surgical Management, The Role of Systemic Therapy, Shortcomings and Future Directions. J Am Acad Dermatol. 2025 Jan 07. Jaguan D, Thakker S, Belzberg M, Gulati N, Campbell JR, DeClerck BK, Patel VA, In GK. PMID: 39788429.
      View in: PubMed   Mentions:    Fields:    
    6. Social health, activity behaviors, and quality of life among young adult cancer survivors: Protocol for a prospective observational study. PLoS One. 2024; 19(11):e0309924. Miller KA, Kaslander JN, Stal J, Belcher BR, Cho J, Freyer DR, de la Haye K, Milam JE, Piombo SE, Cairns M, Hewus M, Marin P, In GK. PMID: 39514565; PMCID: PMC11548772.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Ancestry and somatic profile predict acral melanoma origin and prognosis. medRxiv. 2024 Sep 23. Basurto-Lozada P, Vázquez-Cruz ME, Molina-Aguilar C, Jiang A, Deacon DC, Cerrato-Izaguirre D, Simonin-Wilmer I, Arriaga-González FG, Contreras-Ramírez KL, Dawson ET, Wong-Ramirez JRC, Ramos-Galguera JI, Álvarez-Cano A, García-Ortega DY, García-Salinas OI, Hidalgo-Miranda A, Cisneros-Villanueva M, Martínez-Said H, Arends MJ, Ferreira I, Tullett M, Olvera-León R, van der Weyden L, Del Castillo Velasco Herrera M, Roldán-Marín R, Vidaurri de la Cruz H, Tavares-de-la-Paz LA, Hinojosa-Ugarte D, Belote RL, Bishop DT, Díaz-Gay M, Alexandrov LB, Sánchez-Pérez Y, In GK, White RM, Possik PA, Judson-Torres RL, Adams DJ, Robles-Espinoza CD. PMID: 39399030; PMCID: PMC11469390.
      View in: PubMed   Mentions:
    8. A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma. Gynecol Oncol. 2024 Sep; 188:13-21. Wilhite AM, Wu S, Xiu J, Gibney GT, Phung T, In GK, Herzog TJ, Khabele D, Erickson BK, Brown J, Rocconi RP, Pierce JY, Scalici JM, Jones NL. PMID: 38861917.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    9. Influence of Anatomic Locations of T1b Melanomas and Patient Age on Outcomes. J Drugs Dermatol. 2024 May 01; 23(5):306-310. Huang MY, Chen A, Quarshie C, Masson R, Barajas G, Kim G, DeClerck B, Swanson MS, In GK, Kokot N, Pickering TA, Hu JC. PMID: 38709694.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. Clinicopathologic comparison of basal cell carcinoma among a diverse patient population in Los Angeles County. Skin Health Dis. 2024 Aug; 4(4):e379. Choi E, Oberg MA, Hijazi M, Hall L, Miller KA, Mehta A, Capone S, In GK. PMID: 39104648; PMCID: PMC11297426.
      View in: PubMed   Mentions:
    11. Cutaneous adverse effects induced by tebentafusp in patients with metastatic uveal melanoma: a case series and treatment insights. Clin Exp Dermatol. 2024 Mar 21; 49(4):392-394. Rodriguez I, Norman T, Guenther J, Smart K, Kwong A, Berry J, In GK, Worswick S. PMID: 37956104.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    12. Innate and adaptive immune cell interaction drives inflammasome activation and hepatocyte apoptosis in murine liver injury from immune checkpoint inhibitors. Cell Death Dis. 2024 02 14; 15(2):140. Shojaie L, Bogdanov JM, Alavifard H, Mohamed MG, Baktash A, Ali M, Mahov S, Murray S, Kanel GC, Liu ZX, Ito F, In GK, Merchant A, Stohl W, Dara L. PMID: 38355725; PMCID: PMC10866933.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    13. Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases. NPJ Precis Oncol. 2023 Nov 14; 7(1):120. In GK, Ribeiro JR, Yin J, Xiu J, Bustos MA, Ito F, Chow F, Zada G, Hwang L, Salama AKS, Park SJ, Moser JC, Darabi S, Domingo-Musibay E, Ascierto ML, Margolin K, Lutzky J, Gibney GT, Atkins MB, Izar B, Hoon DSB, VanderWalde AM. PMID: 37964004; PMCID: PMC10646102.
      View in: PubMed   Mentions: 10  
    14. Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus. Front Endocrinol (Lausanne). 2023; 14:1242830. Hilder R, Tsai K, Quandt Z, Isaacs D, Drakaki A, Xing Y, In GK, Angell TE, Lechner MG. PMID: 38027216; PMCID: PMC10643762.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    15. Intraocular Spread of Ocular Surface Squamous Neoplasia Presenting as a Postoperative Anterior Chamber Opacity after Excisional Biopsy. Case Rep Ophthalmol. 2023 Jan-Dec; 14(1):194-202. Pike S, Engelhard SB, Sibug Saber ME, Matthew AJ, In GK, Berry JL. PMID: 37187670; PMCID: PMC10176191.
      View in: PubMed   Mentions:
    16. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023 03 02; 388(9):813-823. Patel SP, Othus M, Chen Y, Wright GP, Yost KJ, Hyngstrom JR, Hu-Lieskovan S, Lao CD, Fecher LA, Truong TG, Eisenstein JL, Chandra S, Sosman JA, Kendra KL, Wu RC, Devoe CE, Deutsch GB, Hegde A, Khalil M, Mangla A, Reese AM, Ross MI, Poklepovic AS, Phan GQ, Onitilo AA, Yasar DG, Powers BC, Doolittle GC, In GK, Kokot N, Gibney GT, Atkins MB, Shaheen M, Warneke JA, Ikeguchi A, Najera JE, Chmielowski B, Crompton JG, Floyd JD, Hsueh E, Margolin KA, Chow WA, Grossmann KF, Dietrich E, Prieto VG, Lowe MC, Buchbinder EI, Kirkwood JM, Korde L, Moon J, Sharon E, Sondak VK, Ribas A. PMID: 36856617; PMCID: PMC10410527.
      View in: PubMed   Mentions: 210     Fields:    Translation:HumansCTClinical Trials
    17. Prevalence and correlates of skin examination among ethnically diverse young adult survivors of childhood cancer. Cancer Med. 2023 04; 12(7):8557-8566. Miller KA, Li AA, Wojcik KY, Stal J, Cockburn MG, In GK, Freyer DR, Hamilton AS, Milam JE. PMID: 36495004; PMCID: PMC10134373.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    18. A retrospective analysis of rates of dermatology follow-up and new skin cancer diagnosis among solid organ transplant recipients during the COVID-19 pandemic. JAAD Int. 2023 Mar; 10:53-54. Saranath R, Fernandez B, Gomez J, Miller M, Novack D, Parvathala N, Shah E, Wong-Michalak S, Rodman J, Fong MW, Ganesh S, Han H, In GK, Kahn J, Liebler J, Maw TT, Miller K, Smogorzewski M, Hu J, Ngo B, Ahronowitz I. PMID: 36636104; PMCID: PMC9829740.
      View in: PubMed   Mentions: 2  
    19. Social networks of oncology clinicians as a means for increasing survivorship clinic referral. Commun Med (Lond). 2022; 2:89. Piombo SE, Miller KA, Freyer DR, Milam JE, Ritt-Olson A, In GK, Valente TW. PMID: 35856083; PMCID: PMC9287406.
      View in: PubMed   Mentions:
    20. Development of a core outcome set for basal cell carcinoma. J Am Acad Dermatol. 2022 09; 87(3):573-581. Schlessinger DI, Reynolds KA, Dirr MA, Ibrahim SA, Yanes AF, Lazaroff JM, Godinez-Puig V, Chen BR, Kurta AO, Cotseones JK, Chiren SG, Furlan KC, Iyengar S, Behshad R, DeHoratius DM, Denes P, Drucker AM, Dzubow LM, Etzkorn JR, Harwood CA, Kim JYS, Lawrence N, Lee EH, Lissner GS, Marghoob AA, Matin RN, Mattox AR, Mittal BB, Thomas JR, Zhou XA, Zloty D, Schmitt J, Kirkham JJ, Armstrong AW, Basset-Seguin N, Billingsley EM, Bordeaux JS, Brewer J, Brown M, Brown M, Collins SAB, Fargnoli MC, De Azevedo SJ, Dummer R, Eggermont A, Goldman GD, Haedersdal M, Hale EK, Hanlon A, Harms KL, Huang CC, Hurst EA, In GK, Kelleners-Smeets N, Kheterpal M, Leshin B, Mcdonald M, Miller SJ, Miller A, Mostow EN, Trakatelli M, Nehal KS, Ratner D, Rogers H, Sarin KY, Soon SL, Stasko T, Storrs PA, Tagliaferri L, Vidimos AT, Wong SL, Yu SS, Zalaudek I, Zeitouni NC, Zitelli JA, Poon E, Sobanko JF, Cartee TV, Maher IA, Alam M. PMID: 35551965.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    21. Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma. J Immunother Cancer. 2022 05; 10(5). In GK, Nallagangula A, Choi JS, Tachiki L, Blackburn MJ, Capone S, Bollin KB, Reuben DY, Shirai K, Zhang-Nunes S, Ragab O, Terando A, Hu JC, Lee H, Bhatia S, Chandra S, Lutzky J, Gibney GT. PMID: 35545318; PMCID: PMC9096532.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    22. Transcriptional Profiling of Malignant Melanoma Reveals Novel and Potentially Targetable Gene Fusions. Cancers (Basel). 2022 Mar 15; 14(6). Darabi S, Elliott A, Braxton DR, Zeng J, Hodges K, Poorman K, Swensen J, Shanthappa BU, Hinton JP, Gibney GT, Moser J, Phung T, Atkins MB, In GK, Korn WM, Eisenberg BL, Demeure MJ. PMID: 35326655; PMCID: PMC8946593.
      View in: PubMed   Mentions:
    23. Factors Associated With Hospitalization Among Breast Cancer Patients With COVID-19: A Diverse Multi-Center Los Angeles Cohort Study. Clin Breast Cancer. 2022 06; 22(4):e558-e566. Kathuria-Prakash N, Antrim L, Hornstein N, Sun AW, Kang IM, Baclig NV, Angell TE, Lechner MG, Wald-Dickler N, In GK. PMID: 35027318; PMCID: PMC8677421.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    24. Disparities in nonmelanoma skin cancer in Hispanic/Latino patients based on Mohs micrographic surgery defect size: A multicenter retrospective study. J Am Acad Dermatol. 2022 02; 86(2):353-358. Blumenthal LY, Arzeno J, Syder N, Rabi S, Huang M, Castellanos E, Tran P, Pickering TA, Dantus EJ, In GK, Soriano T, Hu JC. PMID: 34624413; PMCID: PMC8810691.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    25. Characterizing DNA methylation signatures and their potential functional roles in Merkel cell carcinoma. Genome Med. 2021 08 16; 13(1):130. Gujar H, Mehta A, Li HT, Tsai YC, Qiu X, Weisenberger DJ, Jasiulionis MG, In GK, Liang G. PMID: 34399838; PMCID: PMC8365948.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    26. Acral lentiginous melanoma-Population, treatment, and survival using the NCDB from 2004 to 2015. Pigment Cell Melanoma Res. 2021 11; 34(6):1049-1061. Bian SX, Hwang L, Hwang J, Ragab O, In GK, Peng D, Lin E. PMID: 34273249; PMCID: PMC8599631.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    27. 18F-FDG PET/CT Monitoring of Response to Programmed Death Protein 1 Blockade in Metastatic Basal Cell Carcinoma. Clin Nucl Med. 2021 Aug 01; 46(8):e436-e437. Jadvar H, In GK. PMID: 33512957; PMCID: PMC8243770.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    28. Cutaneous Malignancies of the Head and Neck. Hematol Oncol Clin North Am. 2021 10; 35(5):991-1008. In GK, Thomas JS, Silk AW. PMID: 34281755.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    29. A Case Series of Multiple Primary Malignancies Among Patients With Advanced Melanoma. Cureus. 2021 Jun; 13(6):e15480. Ebia MI, Capone S, Ricker C, Thomas JS, Tulpule V, Kang I, D'Souza A, Freyer DR, Miller K, In GK. PMID: 34262818; PMCID: PMC8260217.
      View in: PubMed   Mentions: 3  
    30. Examining low rates of dermatology visits in solid organ transplant recipients. J Am Acad Dermatol. 2022 06; 86(6):1369-1372. Fernandez B, Miller M, Sierro T, Shah E, Wong-Michalak S, Haughton R, Rodman J, Fong ME, Ganesh S, Han H, In GK, Maw TT, Miller K, Smogorzewski M, Hu J, Ngo B, Ahronowitz I. PMID: 34058274.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    31. The time to offer treatments for COVID-19. Expert Opin Investig Drugs. 2021 May; 30(5):505-518. Ngo BT, Marik P, Kory P, Shapiro L, Thomadsen R, Iglesias J, Ditmore S, Rendell M, Varon J, Dubé M, Nanda N, In G, Arkfeld D, Chaudhary P, Campese VM, Hanna DL, Sawcer DE, Ehresmann G, Peng D, Smogorewski M, Armstrong A, Dasgupta R, Sattler F, Brennan-Rieder D, Mussini C, Mitja O, Soriano V, Peschanski N, Hayem G, Confalonieri M, Piccirillo MC, Lobo-Ferreira A, Bello Rivero I, Turkia M, Vinjevoll EH, Griffin D, Hung IF. PMID: 33721548; PMCID: PMC8074648.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    32. Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922). Melanoma Res. 2021 04 01; 31(2):162-172. Moschos SJ, Eroglu Z, Khushalani NI, Kendra KL, Ansstas G, In GK, Wang P, Liu G, Collichio FA, Googe PB, Carson CC, McKinnon K, Wang HH, Nikolaishvilli-Feinberg N, Ivanova A, Arrowood CC, Garrett-Mead N, Conway KC, Edmiston SN, Ollila DW, Serody JS, Thomas NE, Ivy SP, Agrawal L, Dees EC, Abbruzzese JL. PMID: 33661190; PMCID: PMC8025369.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    33. Rapidly Progressive Porocarcinoma of the Ear and Multidisciplinary Approach to Management. Dermatol Surg. 2021 03 01; 47(3):404-406. Rabi S, Syder N, Ragab O, In G, Hu JC. PMID: 32141925.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    34. The Importance of Understanding the Stages of COVID-19 in Treatment and Trials. AIDS Rev. 2021 02 08; 23(1):40-47. Griffin DO, Brennan-Rieder D, Ngo B, Kory P, Confalonieri M, Shapiro L, Iglesias J, Dube M, Nanda N, In GK, Arkfeld D, Chaudhary P, Campese VM, Hanna DL, Sawcer D, Ehresmann G, Peng D, Smorgorzewski M, Amstrong A, Vinjevoll EH, Dasgupta R, Sattler FR, Mussini C, Mitjà O, Soriano V, Peschanski N, Hayem G, Piccirillo MC, Lobo-Ferreira A, Rivero IB, Hung IFH, Rendell M, Ditmore S, Varon J, Marik P. PMID: 33556957.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCells
    35. COVID-19 Outcomes of Patients With Differentiated Thyroid Cancer: A Multicenter Los Angeles Cohort Study. Endocr Pract. 2021 Feb; 27(2):90-94. Kathuria-Prakash N, Mosaferi T, Xie M, Antrim L, Angell TE, In GK, Su MA, Lechner MG. PMID: 33551317; PMCID: PMC7831810.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    36. Impact of COVID-19 infection among cancer patients treated at the Los Angeles County Medical Center. Cancer Treat Res Commun. 2021; 26:100273. Antrim L, Capone S, Dong S, Chung D, Lin S, Wald-Dickler N, In GK. PMID: 33338856; PMCID: PMC7728418.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    37. PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California. J Cancer Res Clin Oncol. 2021 Jun; 147(6):1803-1811. In GK, Vaidya P, Filkins A, Hermel DJ, King KG, Ragab O, Tseng WW, Swanson M, Kokot N, Lang JE, Menendez L, DeClerck B, Kim G, Hu JC, Terando A, Jadvar H, Ricker C, Miller KA, Peng DH, Wysong A. PMID: 33210210.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    38. Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database. Exp Biol Med (Maywood). 2021 01; 246(1):31-39. Owsley J, Stein MK, Porter J, In GK, Salem M, O'Day S, Elliott A, Poorman K, Gibney G, VanderWalde A. PMID: 33019809; PMCID: PMC7797994.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    39. Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases. Oncotarget. 2020 Aug 18; 11(33):3118-3128. In GK, Poorman K, Saul M, O'Day S, Farma JM, Olszanski AJ, Gordon MS, Thomas JS, Eisenberg B, Flaherty L, Weise A, Daveluy S, Gibney G, Atkins MB, Vanderwalde A. PMID: 32913556; PMCID: PMC7443369.
      View in: PubMed   Mentions: 15     Fields:    
    40. Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget's disease. Cancer Med. 2020 02; 9(4):1441-1450. Gatalica Z, Vranic S, Krušlin B, Poorman K, Stafford P, Kacerovska D, Senarathne W, Florento E, Contreras E, Leary A, Choi A, In GK. PMID: 31899853; PMCID: PMC7013075.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    41. Clinical Update on Checkpoint Inhibitor Therapy for Conjunctival and Eyelid Melanoma. Int Ophthalmol Clin. 2020; 60(2):77-89. Lu JE, Chang JR, Berry JL, In GK, Zhang-Nunes S. PMID: 32205655; PMCID: PMC8059069.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    42. Prevalence and correlates of adherence to skin examination among adolescent and young adult survivors of melanoma from the Project Forward Study. Pediatr Blood Cancer. 2020 03; 67(3):e28090. Miller KA, Wojcik KY, Cockburn MG, In GK, Hamilton AS, Milam JE. PMID: 31774240; PMCID: PMC6980887.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    43. Concurrent radiation therapy with programmed cell death protein 1 inhibition leads to a complete response in advanced cutaneous squamous cell carcinoma. JAAD Case Rep. 2019 Sep; 5(9):763-766. Vaidya P, Mehta A, Ragab O, Lin S, In GK. PMID: 31516991; PMCID: PMC6728732.
      View in: PubMed   Mentions: 6  
    44. Skin cancer and dermatoses in a majority-Hispanic population of solid organ transplant recipients. J Am Acad Dermatol. 2020 Aug; 83(2):607-610. Adler BL, Smogorzewski J, Sierro T, Shauly O, Osipchuk D, Miller M, Mert M, Fong MW, Ganesh S, Han H, In GK, Maw TT, Smogorzewski M, Hu J, Ngo B, Lee D, Ahronowitz I. PMID: 31400454; PMCID: PMC7004884.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    45. Two synchronous malignancies: nodular melanoma and renal cell carcinoma in a patient with an underlying germline BRCA2 mutation. BMJ Case Rep. 2019 Jun 20; 12(6). Snow A, Ricker C, In GK. PMID: 31227566; PMCID: PMC6605957.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    46. Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance. Nat Commun. 2019 04 12; 10(1):1693. Li S, Song Y, Quach C, Guo H, Jang GB, Maazi H, Zhao S, Sands NA, Liu Q, In GK, Peng D, Yuan W, Machida K, Yu M, Akbari O, Hagiya A, Yang Y, Punj V, Tang L, Liang C. PMID: 30979895; PMCID: PMC6461621.
      View in: PubMed   Mentions: 90     Fields:    Translation:HumansAnimalsCells
    47. Cetuximab as a Component of Multimodality Treatment of High-Risk Cutaneous Squamous Cell Carcinoma: A Retrospective Analysis From a Single Tertiary Academic Medical Center. Dermatol Surg. 2019 02; 45(2):254-267. Trodello C, Higgins S, Ahadiat O, Ragab O, In G, Hawkins M, Wysong A. PMID: 30672860.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    48. Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma. JAAD Case Rep. 2018 Nov; 4(10):1004-1006. Lara KM, In GK, Matcuk GR, Mehta A, Hu JS. PMID: 30450405; PMCID: PMC6226586.
      View in: PubMed   Mentions: 8  
    49. Eccrine Porocarcinoma: New Insights and a Systematic Review of the Literature. Dermatol Surg. 2018 10; 44(10):1247-1261. Nazemi A, Higgins S, Swift R, In G, Miller K, Wysong A. PMID: 29894433.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    50. Development of metastatic brain disease involves progression through lung metastases in EGFR mutated non-small cell lung cancer. Converg Sci Phys Oncol. 2017 Sep; 3(3). In G, Mason J, Lin S, Newton PK, Kuhn P, Nieva J. PMID: 30283700; PMCID: PMC6166474.
      View in: PubMed   Mentions: 3  
    51. Development of metastatic brain disease involves progression through lung metastases in EGFR mutated non-small cell lung cancer. Convergent Science Physical Oncology. 2017; 3(3). In GK, Mason J, Lin S, Newton P, Kuhn P, Nieva J.
    52. Skin Cancer Prevention Among Hispanics: a Review of the Literature. Epidemiology. 2017. Miller KA, In GK, Jiang SY, Ahadiat O, Higgins S, Wysong A, Cockburn MG.
    53. Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. Ther Adv Med Oncol. 2017 Aug; 9(8):533-550. In GK, Hu JS, Tseng WW. PMID: 28794805; PMCID: PMC5524246.
      View in: PubMed   Mentions: 46  
    54. Emerging Chemotherapy Agents in Lung Cancer: Nanoparticle Therapeutics for Non-Small Cell Lung Cancer. Transl Cancer Res. 2015; 4(4):340-355. In GK, Nieva J. View Publication.
    55. Chemotherapy for Good-Risk Nonseminomatous Germ Cell Tumors: Current Concepts and Controversies. Urol Clin North Am. 2015 Aug; 42(3):347-57. In G, Dorff T. PMID: 26216822; PMCID: PMC9484323.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    Gino's Networks
    Concepts (169)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (74)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.

    This site is running Profiles RNS version UCSF-v3.1.0-15-g9ae42700 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.